The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

NCT05431504 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Dalpiciclib in combination with endocrine therapy by Physicians choice

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]